The IN were sampled during and after ICB and sequenced to identify gene expression signatures that correlated with sensitivity or resistance. We also analyzed gene expression at the IN prior to ICB treatment to identify markers predicting therapeutic response. Longitudinally interrogating an IN, to monitor changes associated with ICB response, presents a new opportunity to personalize care and investigate mechanisms underlying treatment resistance.
